A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.
This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors. Patients received intravenous doses every 3 weeks of nelistotug 2.
This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors. Patients received intravenous doses every 3 weeks of nelistotug 2.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Clin Cancer Res
Why it surfaced
Matched watchlist topic 'Novel therapeutics: immunotherapy, CAR-T, targeted therapy'. Study design: Randomized Controlled Trial (inferred). Score: 9/10 (N:3, R:2, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.